尿血安合剂联合来氟米特对IgA肾病患者VEGF、NF-κB表达的影响及可行性与安全性分析

Effects of Niaoxue’an mixture combined with leflunomide on the expressions of VEGF and NF-κB in patients with IgA nephropathy and their feasibility and safety

目的分析对IgA肾病患者给予尿血安合剂与来氟米特联合治疗对于其血管内皮生长因子(VEGF)、NF-κB表达的影响与可行性及安全性。方法选取自2015年12月至2018年12月收治的IgA肾病112例患者为观察对象,通过数字随机法将所有患者分为常规组与研究组,每组56例。对常规组患者给予来氟米特治疗,对研究组患者给予尿血安合剂联合来氟米特治疗,比较2组患者在治疗后的临床效果及对VEGF、NF-κB表达的影响。结果2组间患者经治疗后,研究组患治疗效果优于常规组,且VEGF、NF-κB指标水平明显降低(P<0.05);同时研究组患者肾功能指标尿素氮(BUN)、肌酐(Scr)、24 h尿蛋白定量(24 hUP)指标低于常规组,Ccr高于常规组;其尿蛋白、尿红细胞下降幅度优于常规组,而常规组ALT指标增高幅度更大于研究组,组间比较差异有统计学意义(P<0.05);但2组患者治疗后WBC指标变化不大,且研究组ALT指标增幅较低,用药安全性更高,与治疗前比较差异无统计学意义(P>0.05)。结论对IgA肾病患者在临床治疗中给予尿血安合剂与来氟米特联合治疗,可进一步提高临床治疗效果,改善对VEGF、NF-κB指标的表达,并提高临床用药安全性,可在对IgA肾病的治疗中广泛普及与应用。

Objective To investigate the effects of Niaoxue’an mixture combined with leflunomide on the expressions of VEGF and NF-κB in patients with IgA nephropathy and their feasibility and safety.Methods A total of 112 patients with IgA nephropathy who were admitted and treated in our hospital from December 2015 to December 2018 were enrolled as research objects.All the patients were divided into routine treatment group(n=56)and research group(n=56)according to digital random method.The patients in routine treatment group were treated by leflunomide,however,thepatients in research group were treated by Niaoxue’an mixture combined with leflunomide.The clinical curative effects and the effects on the expressions of vascular endothelial growth factor(VEGF)and NF-κB were observed and compared between the two groups.Results After treatment,the therapeutic effects in research group were superior to those in routine treatment group,and the levels of VEGF and NF-κB were significantly lower than those in routine treatment group(P<0.05).Moreover the levels of BUN,Scr and 24hUP in research group were significantly lower than those in routine treatment group(P<0.05),but the Ccr levels were significantly higher than those in routine treatment group(P<0.05).However there were no significant differences in WBC levels after treatment between the two groups(P>0.05),but the increase degree of ALT in research group was significantly lower than that in routine treatment group,with higher safety.Conclusion Niaoxue’an mixture combined with leflunomide in treatment of IgA nephropathy can improve the clinical curative effects,improve the expressions of VEGF and NF-κB,and improve the safety of clinical medication,therefore,it can be widely used in treatment of IgA nephropathy.